Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

The hypothesis for this study is that hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with concurrent carboplatin and paclitaxel, followed by maintenance durvalumab will improve locoregional control at 18 months by 10% compared to standard-fractionated chemo-IMRT/durvalumab. A modest improvement in locoregional control (LRC) was selected as a target which could merit further study of this hypofractionated IMRT regimen in a Phase III trial

Trial Details

NCT ID
NCT04992780
Phase
PHASE2
Sponsor
University of Kansas Medical Center
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Hypo-Fractionation
  • Standard-Fractionation
Locations (sample)
  • Kansas City, Kansas, United States|39.11417,-94.62746
  • Overland Park, Kansas, United States|38.98223,-94.67079
  • Topeka, Kansas, United States|39.04833,-95.67804
  • Kansas City, Missouri, United States|39.09973,-94.57857
  • Lee's Summit, Missouri, United States|38.91084,-94.38217

Key Eligibility Criteria

  • Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written in…
  • Males and females age ≥ 18 years
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 2
  • Measurable disease by RECIST 1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →